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Abstract
Influenza viruses resistant to antiviral drugs emerge frequently. Not surprisingly, the widespread treatment in many
countries of patients infected with 2009 pandemic influenza A (H1N1) viruses with the neuraminidase (NA) inhibitors
oseltamivir and zanamivir has led to the emergence of pandemic strains resistant to these drugs. Sporadic cases of
pandemic influenza have been associated with mutant viruses possessing a histidine-to-tyrosine substitution at position 274
(H274Y) in the NA, a mutation known to be responsible for oseltamivir resistance. Here, we characterized in vitro and in vivo
properties of two pairs of oseltaimivir-sensitive and -resistant (possessing the NA H274Y substitution) 2009 H1N1 pandemic
viruses isolated in different parts of the world. An in vitro NA inhibition assay confirmed that the NA H274Y substitution
confers oseltamivir resistance to 2009 H1N1 pandemic viruses. In mouse lungs, we found no significant difference in
replication between oseltamivir-sensitive and -resistant viruses. In the lungs of mice treated with oseltamivir or even
zanamivir, 2009 H1N1 pandemic viruses with the NA H274Y substitution replicated efficiently. Pathological analysis revealed
that the pathogenicities of the oseltamivir-resistant viruses were comparable to those of their oseltamivir-sensitive
counterparts in ferrets. Further, the oseltamivir-resistant viruses transmitted between ferrets as efficiently as their
oseltamivir-sensitive counterparts. Collectively, these data indicate that oseltamivir-resistant 2009 H1N1 pandemic viruses
with the NA H274Y substitution were comparable to their oseltamivir-sensitive counterparts in their pathogenicity and
transmissibility in animal models. Our findings highlight the possibility that NA H274Y-possessing oseltamivir-resistant 2009
H1N1 pandemic viruses could supersede oseltamivir-sensitive viruses, as occurred with seasonal H1N1 viruses.
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Since its emergence in early spring of 2009, 2009 pandemic
influenza A (H1N1) viruses have been circulating worldwide [1].
Although most infected individuals have exhibited an uncompli-
cated, mild respiratory disorder, the pathogenicity of this virus is
clearly higher than that of seasonal influenza viruses in animal
models [2–4] and humans, including those who do not have
underlying illness [5].
Although two classes of anti-influenza drugs – M2 ion channel
blockers (amino-adamantines; amantadine and rimantadine) and
neuraminidase (NA) inhibitors (oseltamivir and zanamivir) – are
licensed, the 2009 H1N1 pandemic viruses, including the earliest
isolate, are already amino-adamantine-resistant [1]. By contrast,
most of the currently circulating pandemic viruses are susceptible
to NA inhibitors [2,6], and therefore, pandemic influenza patients
are treated with NA inhibitors in many countries. This widespread
administration, however, raises concerns over the emergence and
global spread of NA inhibitor-resistant 2009 H1N1 pandemic
viruses.
Studies with seasonal H1N1, H3N2, and highly pathogenic
avian H5N1 viruses revealed that single amino acid substitutions
at several positions in or around the NA active site confer
resistance to viruses against NA inhibitors [7–11]. Among these
NA substitutions, a histidine-to-tyrosine substitution at position
274 (N2 numbering, H274Y) is one of the best characterized
oseltamivir-resistant markers. Recently, the NA H274Y substitu-
tion has been detected in sporadic cases of oseltamivir-treated and
PLoS Pathogens | www.plospathogens.org 1 August 2010 | Volume 6 | Issue 8 | e1001079-untreated patients infected with 2009 H1N1 pandemic viruses
[12–14]: however, the pathogenicity and transmissibility of viruses
possessing this NA substitution remain unknown.
To better assess the risk of the 2009 H1N1 pandemic viruses
that possess the NA H274Y substitution, we studied the in vitro and
in vivo properties of two NA H274Y-possessing isolates that
emerged independently: A/Osaka/180/2009 (H1N1; O180r) and
A/Vietnam/HN32060/2009 (H1N1; VN32060r).
Results/Discussion
In vitro sensitivity of viruses to NA inhibitors
To test the in vitro sensitivity to various NA inhibitors of 2009
H1N1 pandemic viruses possessing the NA H274Y substitution,
we measured the NA activity of O180r and VN32060r exposed to
oseltamivir carboxylate (the active metabolite of oseltamivir),
zanamivir, or R-125489 (the active metabolite of the experimental
NA inhibitor CS-8958) and determined IC50 values. These IC50
values were compared with those of A/Osaka/164/2009 (O164s)
and A/Vietnam/HCM9727/2009 (VN9727s), both of which do
not possess the NA substitution (Supplementary Table S1) and
thus served as control strains (Table 1). O164s and O180r were
isolated on similar dates, circulating in the same community and
were genetically similar. Likewise, VN9727s and VN32060r were
similar with respect to their isolation history (temporally and
geographically) and their genetic properties. The IC50 values of
O180r and VN32060r were about 500-fold higher than those of
O164s and VN9727s for oseltamivir, while the sensitivity to
zanamivir and R-125489 was comparable for all viruses tested.
To further assess the in vitro sensitivity of oseltamivir-resistant
2009 H1N1 pandemic viruses to the NA inhibitors, we
investigated the growth kinetics of the two pairs of oseltaimivir-
sensitive and -resistant viruses in cultured cells in the presence of
oseltamivir carboxylate, zanamivir, or R-125489 (Supplementary
Fig. S1). While the growth of O164s and VN9727s was severely
impaired by oseltamivir carboxylate, O180r and VN32060r
replicated efficiently even in the presence of oseltamivir carbox-
ylate. By contrast, both zanamivir and R-125489 inhibited the
replication of all of the viruses tested. These results indicate that
the NA H274Y substitution reduces the sensitivity of 2009 H1N1
pandemic viruses to oseltamivir, as has been shown with seasonal
H1N1, H3N2, and highly pathogenic avian H5N1 viruses [7–
11,15], since the other amino acid variations among the viruses
tested (Supplementary Table S1) did not account for their reduced
oseltamivir sensitivity: the lower growth of O180r compared to
that of O164s in the absence of antivirals (Supplementary Fig. S1)
might be due to these additional amino acid differences.
Replication and antiviral sensitivity of viruses in mice
To evaluate the effect of the NA H274Y substitution on the
replication of the 2009 pandemic viruses in vivo, we infected
BALB/c mice with either 10
2 or 10
3 plaque-forming units (PFU) of
O164s, VN9727s, O180r, or VN32060r and determined virus
titers in the lungs of mice on days 3 and 6 post-infection (pi) (Fig. 1,
see ‘‘Control’’ samples). We found that oseltamivir-resistant viruses
replicated significantly better than oseltamivir-sensitive viruses at
both day 3 and day 6 pi with one exception: on day 6 pi, the virus
titer in the lungs of mice infected with 10
3 PFU of VN9727s was
significantly higher than that of VN32060r-infected mice. These
results indicate that the NA H274Y substitution does not
negatively affect virus replication in the mouse lung in most
settings.
Next, we tested virus sensitivity to anti-influenza drugs in mice
(Fig. 1). One hour pi, mice received oseltamivir, zanamivir, CS-
8958, or an experimental viral RNA polymerase inhibitor
favipiravir (also known as T-705). When mice were treated with
oseltamivir (80 mg/kg/day dose), the replication of the NA
H274Y-possessing viruses O180r and VN32060r was not
inhibited, whereas the virus titers of their oseltamivir-sensitive
counterparts O164s and VN9727s were significantly reduced.
These results support the results of the in vitro NA inhibition assays
and growth kinetics in MDCK cells indicates that the NA H274Y
substitution confers oseltamivir resistance to viruses in mice.
Although the efficacy of zanamivir against an oseltamivir-resistant
virus (O180r) was not prominent when mice were infected with
10
3 PFU of viruses (Fig. 1), at a lower infectious dose (10
2 PFU) of
viruses, its efficacy was apparent. CS-8958 and favipiravir
significantly reduced the replication of all viruses tested, indicating
that these 2009 H1N1 pandemic isolates, including oseltamivir-
resistant strains, are as susceptible to these experimental antiviral
drugs as one of the initial isolates A/California/04/2009 (H1N1)
[2].
Pathogenicity and transmissibility of viruses in ferrets
To assess the transmissibility of oseltamivir-resistant 2009 H1N1
pandemic viruses, on day 1 pi we co-housed naı ¨ve ferrets in
perforated cages next to ferrets inoculated with 10
6 PFU of O164s,
VN9727s, O180r, or VN32060r and collected nasal swabs from
inoculated and contact ferrets on days 1, 3, 5, 7, 9, and 11 after
infection and co-housing, respectively, for virological analysis
(Table 2). For all viruses tested, all contact ferrets were infected
with viruses via respiratory droplets from infected ferrets, although
the detection of O180r in contact ferrets was delayed by up to two
Table 1. In vitro virus susceptibility to NA inhibitors.
NA inhibitors IC50
c
O164s O180r VN9727s VN32060r
Oseltamivir carboxylate
a 1.6
c 856 1.63 811
Zanamivir 0.43 0.75 0.3 0.56
R-125489
b 0.44 0.89 0.26 0.5
aOseltamivir carboxylate is the active form of oseltamivir.
bR-125489 is the active form of CS-8958.
cIC50 value: 50% inhibitory concentration (nM) of duplicate reactions.
doi:10.1371/journal.ppat.1001079.t001
Author Summary
Although most of the currently circulating 2009 pandemic
influenza A (H1N1) viruses are susceptible to neuramini-
dase (NA) inhibitors (oseltamivir and zanamivir), oseltami-
vir-resistant mutants have sporadically appeared. Yet, the
pathogenicity and transmissibility of these oseltamivir-
resistant 2009 H1N1 pandemic viruses remain unknown.
Here, we compared the pathogenicity and transmissibility
of two pairs of oseltamivir-sensitive and -resistant viruses
in mouse and ferret models. We found that the
oseltamivir-resistant viruses efficiently replicated in the
lungs of mice treated with oseltamivir or even zanamivir.
Further, we demonstrated that these oseltamivir-resistant
viruses caused lung lesions in ferrets and efficiently
transmitted between ferrets, as did their oseltamivir-
sensitive counterparts. Overall, our results suggest the
possibility that oseltamivir-resistant viruses could spread
among humans without loss of pathogenicity.
Oseltamivir-Resistant Pandemic Viruses
PLoS Pathogens | www.plospathogens.org 2 August 2010 | Volume 6 | Issue 8 | e1001079Figure 1. Antiviral sensitivity of viruses in mice. Mice were intranasally inoculated with 10
2 (A, D, G, and J) or 10
3 PFU of O164s, O180r (A–F),
VN9727s, or VN32060r (G–L). At one hour post-infection (pi), mice were administered oseltamivir, zanamivir, CS-8958, favipiravir, or distilled water and
PBS (control). Ten (A, B, D, E, G, H, J, and K) or three (C, F, I, and L) mice per group were euthanized on days 3 and 6 pi and virus titers in the lungs
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oseltamivir-resistant viruses (i.e., O180r and VN32060r) revealed
that all of the viruses isolated from the contact ferrets retained the
oseltamivir resistance-conferring tyrosine at position 274 in NA.
Collectively, there were no substantial differences in transmissi-
bility between oseltamivir-sensitive and -resistant viruses in ferrets.
To evaluate the pathogenicity of NA H274Y-possessing
oseltamivir-resistant 2009 H1N1 pandemic viruses, we infected
ferrets with 10
6 PFU of O164s, VN9727s, O180r, or VN32060r
and monitored them daily for changes in body temperature and
weight, and for clinical signs. On day 6 pi, nasal turbinates,
trachea, and lungs were removed for pathological analysis. All
viruses tested caused respiratory symptoms such as sneezing,
although no marked changes in body temperature or weight were
observed (data not shown). We found no remarkable pathological
differences in the extent and manifestation of disease between
ferrets infected with oseltamivir-sensitive or -resistant viruses
(Fig. 2). All ferrets examined had severe inflammatory changes
in their respiratory tracts: rhinitis, tracheitis and bronchopneu-
monia with bronchadenitis (Fig. 2A and B). In addition, we found
limited bronchadenitis lesions with viral antigens in four ferrets,
two of which were infected with oseltamivir-sensitive viruses (either
O164s or VN9727s) while the other two were infected with
oseltamivir-resistant VN32060r (Fig. 2C and D). These results
indicate the comparable pathogenicity of the oseltamivir-resistant
viruses to their oseltamivir-sensitive counterparts in ferrets. These
results also suggest that the oseltamivir-resistant 2009 H1N1
pandemic viruses have the potential to be readily transmitted
among humans without loss of pathogenicity.
Here, we investigated antiviral sensitivity, pathogenicity, and
transmissibility of 2009 H1N1 pandemic influenza viruses possess-
ing the substitution NA H274Y, which is known to reduce the
sensitivity of influenza viruses to oseltamivir in cultured cells, mice,
and ferrets. Viruses with this NA substitution exhibited reduced
sensitivitytooseltamivirwithcomparable replication,pathogenicity,
and transmissibility compared to their oseltamivir-sensitive coun-
terparts: these findings need to be validated in humans. The
widespread administration of oseltamivir, and to a lesser extent
zanamivir, will clearly contribute to the emergence of NA inhibitor-
resistant viruses that retain optimal replication fitness and
transmissibility in humans. Given our finding that the oseltamivir-
resistant 2009 H1N1 pandemic viruses are as pathogenic and
transmissibleastheirdrug-sensitivecounterparts, specificcriteria for
the use of NA inhibitors may need to be reconsidered.
Oseltamivir has been used extensively in patients with 2009
pandemic influenza, especially those who are immunocompro-
mised. Approximately one-third of the oseltamivir-resistant
pandemic strains have been isolated from immunocompromised
patients (http://www.who.int/csr/disease/swineflu/frequently_
asked_questions/antivirals/resistance/en/index.html), a possibili-
ty we predicted early in this pandemic [16]. Oseltamivir-resistant
viruses readily emerge in immunocompromised patients partly
because viruses can replicate to higher titers and for longer periods
in immunocompromised hosts compared to those who are
immunocompetent hosts [17]. Since the oseltamivir-resistant
2009 pandemic viruses are as pathogenic and transmissible as
their drug-sensitive parents, immunocompromised influenza
patients require special care - increased drug doses, combination
therapy, and possibly isolation. In particular, combination therapy
has the potential to reduce the emergence of drug-resistant
mutants [18] and provide synergistic effects on the inhibition of
virus replication [19–21] with no increase in adverse events [22].
Adopting such measures would help prevent the situation
experienced with the oseltamivir-resistant seasonal H1N1 virus,
which emerged during the 2007-2008 influenza season in Europe
[23], spread, and superseded previously circulating oseltamivir-
sensitive viruses [24,25].
Finally, our in vitro and in vivo experiments suggest that the
experimental drugs CS-8958 and favipiravir may be promising
candidates to combat 2009 H1N1 pandemic viruses.
Table 2. Virus titers in the nasal swabs of inoculated and contact ferrets
a.
Virus titer (log10 PFU/ml) in animals infected with:
O164s O180r VN9727s VN32060r





d 6.1 - 5.9 - 4.7 - 4.3 - 5.8 - 7.1 2.9 6.4 2.3 6.6 2.6 4.8 2.5 5.4 2.1 5.6 4.8
Day 3 5.1 1 4.5 3.7 4.2 2.0 3.8 - 3.0 - 2.0 - 5.2 7.4 4.6 5.3 4.8 5.8 4.2 5.8 4.4 4.9 6.1 5.2
Day 5 3.7 5.7 2.1 4.7 2.8 6.1 3.1 6.4 3.2 5.4 2.7 3 4.8 4.8 4.8 3.1 4.6 5.1 1.8 4.2 4.4 4.8 2.6 4.1
Day 7 - - - 5.5 - 4.1 - 5.1 - 4.7 - 5.3 - 3.6 - - 1.3 - - 2.3 4.4 1.8 - 1.7
D a y 9----- --1 . 8 -3 -4 . 7 ------------
D a y 1 1 ----- -------------------
aFor pairs of ferrets, one animal was intranasally inoculated with 10
6 PFU of virus (500 ml) (inoculated ferret, i) and one day later, a naı ¨ve ferret was placed in an adjacent
cage (contact ferret, c). Nasal swabs were collected from all animals every other day for virus titration.
bDay 1 of co-housing of contact animals corresponds to Day 2 of infection.
cVirus titers in the nasal swabs were determined by plaque assays in MDCK cells.
d-, virus not detected (detection limit: 1.0 log10 PFU/g).
doi:10.1371/journal.ppat.1001079.t002
were determined by plaque assays in MDCK cells (detection limit: 1.0 log10 PFU/g). Error bars indicate the standard deviations of viral titers detected
in the lungs of ten or three mice. Statistical significance was assessed by use of the Student’s t-test: *, p,0.05, **, p,0.01.
doi:10.1371/journal.ppat.1001079.g001
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Viruses and cells
We used two pairs of H1N1 pandemic virus clinical isolates;
A/Osaka/164/2009 (O164s), A/Osaka/180/2009 (O180r),
A/Vietnam/HCM9727/2009 (VN9727s), and A/Vietnam/
HN32060/2009 (VN32060r). All of the viruses were isolated in
Madin-Darby canine kidney (MDCK) cells, which were main-
tained in Eagle’s minimal essential medium (MEM) supplemented
with 5% newborn calf serum (Sigma, St. Louis, MO) and cultured
at 35uCi n5 %C O 2. Tyrosine at position 275 in the NA of O180r
and VN32060r was confirmed by molecular cloning and
sequencing of 18 individual clones each, while the rest of the
viral genome sequences were determined by direct sequencing of
amplified DNA.
Antiviral compounds
Oseltamivir (oseltamivir phosphate) and oseltamivir carboxylate
(the active metabolite of oseltamivir; GS4104) were prepared from
Tamiflu (Roche Laboratories Inc., Basel, Switzerland). Zanamivir,
CS-8958 (an experimental NA inhibitor), and R-125489 (the
active metabolite of CS-8958) were synthesized at Daiichi Sankyo
Co. Ltd. according to published procedures [26]. Favipiravir (an
experimental broad-spectrum viral RNA polymerase inhibitor,
also known as T-705), was synthesized at Toyama Chemical Co.,
Ltd.
NA inhibition assay
NA activity of viruses in the presence of NA inhibitor was
measured by an NA inhibition assay as described previously
[8,27,28]. Briefly, diluted viruses were mixed with various
concentrations of NA inhibitor in 2-[N-morpholino]ethanesulfonic
acid containing CaCl2 and incubated for 30 min at 37uC. A
fluorescent substrate methylumbelliferyl-N-acetylneuraminic acid
(Sigma) was added to this mixture, which was then incubated for
one hour at 37uC. After adding NaOH in 80% ethanol to the
mixture to stop the reaction, the fluorescence of the solution was
measured at an excitation wavelength of 360 nm and an emission
wavelength of 465 nm and the 50% inhibitory concentration
(IC50) was calculated.
In vitro growth kinetics
MDCK cells were infected with viruses at a multiplicity of
infection of 0.0001. One hour later, oseltamivir carboxylate,
Figure 2. Pathological findings in the lungs of infected ferrets. Ferrets intranasally inoculated with 10
6 PFU of O164s, O180r, VN9727s, or
VN32060r were euthanized on day 6 pi. The nasal turbinates, lungs, and trachea were subjected to pathological examination. (A) Bronchopneumonia
in a ferret infected with VN9727s (H&E staining). (B) Bronchopneumonia in a ferret infected with VN32060r (H&E staining). (C) Viral antigen (brown
pigment) in the lungs of a ferret infected with O164s (immunohistological staining). (D) Viral antigen (brown pigment) in the lungs of a ferret infected
with O180r (immunohistological staining).
doi:10.1371/journal.ppat.1001079.g002
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added to the cells. At 8, 16, 24, 32, 40, and 48 h post-infection (pi),
the supernatants of the infected cells were harvested and subjected
to plaque assays in MDCK cells to determine virus titers.
Experimental infection of mice
Six-week-old female BALB/c mice (Japan SLC Inc., Shizuoka,
Japan) were anesthetized with isoflurane and intranasally infected
with 10
2 or 10
3 plaque-forming units (PFU) (50 ml) of viruses. One
hour pi, six mice per group were administered the following
antiviral compounds: (1) oseltamivir phosphate: 80 mg per kg per
400 ml (divided into two oral administrations per day) for 5 days;
(2) zanamivir: 0.8, 8, or 25 mg per kg per 50 ml in one daily
intranasal administration for 5 days; (3) CS-8958: 0.75 mg per kg
per 50 ml in one intranasal administration; (4) Favipiravir: 60 or
300 mg per kg per 400 ml (divided into two oral administrations
per day) for 5 days; (5) or distilled water orally (200 ml) and PBS
intranasally (50 ml). Three mice per group were euthanized on
days 3 and 6 pi and virus titers in the lungs were determined by
plaque assays in MDCK cells.
Experimental infection of ferrets
Three-to-four-month-old male ferrets (Marshall Farms, Wol-
cott, NY) and six-to-eight-month-old female ferrets (Triple F
Farms, Sayre, PA) were used; animals from Triple F Farms were
used for the transmission study of O164s and O180r, while those
from Marshall Farms were used for the rest of studies. All of the
animals, which were serologically negative for currently circulating
human influenza viruses (including pandemic H1N1 viruses) by
haemagglutination inhibition (HI) assay, were anesthetized with
ketamine and xylazine (5 mg and 0.5 mg per kg of body weight,
respectively) and intranasally infected with 10
6 PFU (500 ml) of
viruses. On day 6 pi, three ferrets per group were euthanized and
their nasal turbinates, trachea, and lungs subjected to virological
and pathological analyses. For the transmission study, on day 1 pi,
three naı ¨ve ferrets per group were co-housed in a perforated cage
adjacent to an inoculated ferret; ferrets were separated by a
perforated divider and did not have direct contact. All ferrets were
monitored daily for changes in body temperature and weight, and
clinical signs. Nasal swabs of inoculated and contact ferrets were
collected on days 1, 3, 5, 7, 9, and 11 after infection and co-
housing, respectively, and virus titers were determined by plaque
assays in MDCK cells.
Pathological examination
Nasal turbinates, lungs, and trachea of euthanized ferrets were
preserved in 10% phosphate-buffered formalin. Tissues were then
processed for paraffin embedding and cut into 5 mm-thick sections.
One section from each tissue sample was subjected to standard
hematoxylin-and-eosin (H&E) staining, while another was pro-
cessed for immunohistological staining with an anti-influenza virus
rabbit antibody (R309; prepared in our laboratory) that reacts
comparably with all viruses tested. Specific antigen-antibody
reactions were visualized by 3,3’-diaminobenzidine tetrahy-
drochloride staining using a Dako EnVision system (Dako Co.
Ltd., Tokyo, Japan).
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Supporting Information
Figure S1 Growth kinetics of viruses in MDCK cells. Cells were
infected with O164s (A), O180r (B), VN9727s (C), or VN32060r
(D) at a multiplicity of infection of 0.0001. One hour later,
oseltamivir carboxylate, zanamivir, R-125489 (10 mM each), or
nothing (control) was added to the cells. The virus titers in the
supernatants at the indicated times post-infection were assessed by
plaque assays in MDCK cells. Error bars indicate the standard
deviations of the viral titers from triplicate experiments.
Found at: doi:10.1371/journal.ppat.1001079.s001 (0.27 MB TIF)
Table S1 Amino acid differences among the viruses tested.
Found at: doi:10.1371/journal.ppat.1001079.s002 (0.16 MB
DOC)
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